LIFE SCIENCES PORTFOLIO – SELECTION

The Triginta Capital portfolio can be divided into the segments MidCap, Life Sciences, T.I.M.E.S. and Applied Technologies. Further investments that have meanwhile been exited can be found Exits.

The Life Sciences portfolio comprises of life science, biotech, pharma and medical technology investments.

		Analyticon Discovery GmbH (TCF2) Developer of compound libraries consisting of natural products and synthetic small molecules www.ac-discovery.com
		Biobase GmbH (IMH) Biological databases, bioinformatics tools and scientific drug-development consulting providing complex molecular biology information and solutions www.biobase.de
		ErgoNex Pharma GmbH (HTB) Development and marketing of Tergurid, a drug for the treatment of several indications including diseases of the central nervous system www.ergonex.com
		Oncotherm GmbH (HTB) Medical technology provider of devices for heat therapy for cancer illnesses (oncothermia) www.oncotherm.de
		Hybrigenics SA (IMH) Development of cancer drugs www.hybrigenics.com
		Lorus Therapeutics Inc. (HTB) Biopharmaceutical company focused on the research and development of cancer therapies www.lorusthera.com
		Neurotech Pharmaceuticals Inc (IMH) Developer of protein-drug delivery systems for the treatment of ophthalmologic diseases such as retinal degeneration (age-related macular degeneration, retinitis pigmentosa) and vascular eye diseases (diabetic retinopathy) www.neurotechusa.com
		SEPIAtec GmbH (TCF2) Provider of equipment for rapid high-throughput HPLC (a physical method for analysis and separation of complex mixtures of compounds) www.sepiatec.com
		TriN Pharma GmbH (HTB) Research and Development of anti-tumordrugs with new mode of action. www.trinpharma.com